 |
|
JAMA-EXPRESS
Comparison of Pioglitazone vs Glimepiride on Progression of Coronary Atherosclerosis in Patients With Type 2 DiabetesThe PERISCOPE Randomized Controlled Trial
Steven E. Nissen, MD;
Stephen J. Nicholls, MBBS, PhD;
Kathy Wolski, MPH;
Richard Nesto, MD;
Stuart Kupfer, MD;
Alfonso Perez, MD;
Horacio Jure, MD;
Robert De Larochellière, MD;
Cezar S. Staniloae, MD;
Kreton Mavromatis, MD;
Jacqueline Saw, MD;
Bo Hu, PhD;
A. Michael Lincoff, MD;
E. Murat Tuzcu, MD; for the PERISCOPE Investigators
JAMA. 2008;299(13):(doi:10.1001/jama.299.13.1561).
Context No antidiabetic regimen has demonstrated the ability to reduce progression of coronary atherosclerosis. Commonly used oral glucose-lowering agents include sulfonylureas, which are insulin secretagogues, and thiazolidinediones, which are insulin sensitizers.
Objective To compare the effects of an insulin sensitizer, pioglitazone, with an insulin secretagogue, glimepiride, on the progression of coronary atherosclerosis in patients with type 2 diabetes.
Design, Setting, and Participants Double-blind, randomized, multicenter trial at 97 academic and community hospitals in North and South America (enrollment August 2003-March 2006) in 543 patients with coronary disease and type 2 diabetes.
Interventions A total of 543 patients underwent coronary intravascular ultrasonography and were randomized to receive glimepiride, 1 to 4 mg, or pioglitazone, 15 to 45 mg, for 18 months with titration to maximum dosage, if tolerated. Atherosclerosis progression was measured by repeat intravascular ultrasonography examination in 360 patients at study completion.
Main Outcome Measure Change in percent atheroma volume (PAV) from baseline to study completion.
Results Least squares mean PAV increased 0.73% (95% CI, 0.33% to 1.12%) with glimepiride and decreased 0.16% (95% CI, –0.57% to 0.25%) with pioglitazone(P = .002). An alternative analysis imputing values for noncompleters based on baseline characteristics showed an increase in PAV of 0.64% (95% CI, 0.23% to 1.05%) for glimepiride and a decrease of 0.06% (–0.47% to 0.35%) for pioglitazone (between-group P = .02). Mean (SD) baseline HbA1c levels were 7.4% (1.0%) in both groups and declined during treatment an average 0.55% (95% CI, –0.68% to –0.42%) with pioglitazone and 0.36% (95% CI, –0.48% to –0.24%) with glimepiride (between-group P = .03). In the pioglitazone group, compared with glimepiride, high-density lipoprotein levels increased 5.7 mg/dL (95% CI, 4.4 to 7.0 mg/dL; 16.0%) vs 0.9 mg/dL (95% CI, –0.3 to 2.1 mg/dL; 4.1%), and median triglyceride levels decreased 16.3 mg/dL (95% CI, –27.7 to –11.0 mg/dL; 15.3%) vs an increase of 3.3 mg/dL (95% CI, –10.7 to 11.7 mg/dL; 0.6%) (P < .001 for both comparisons). Median fasting insulin levels decreased with pioglitazone and increased with glimepiride (P < .001). Hypoglycemia was more common in the glimepiride group and edema, fractures, and decreased hemoglobin levels occurred more frequently in the pioglitazone group.
Conclusion In patients with type 2 diabetes and coronary artery disease, treatment with pioglitazone resulted in a significantly lower rate of progression of coronary atherosclerosis compared with glimepiride.
Trial Registration clinicaltrials.gov Identifier: NCT00225277
Author Affiliations: Department of Cardiovascular Medicine (Drs Nissen, Nicholls, Lincoff, and Tuzcu and Ms Wolski) and Department of Quantitative Health Sciences (Dr Hu), Cleveland Clinic, Cleveland, Ohio; Department of Cardiovascular Medicine, Lahey Clinic, Burlington, Massachusetts (Dr Nesto); Department of Clinical Science, Takeda Global Research and Development, Deerfield, Illinois (Drs Kupfer and Perez); Department of Cardiology, Clinica Chutro, Colon, Argentina (Dr Jure); Department of Cardiology, Quebec Heart Institute, Hôpital Laval, Quebec City, Quebec (Dr De Larochellière); Cardiovascular Division, St Vincent's Hospital Manhattan, New York, New York (Dr Staniloae); Department of Medicine, Division of Cardiology, Atlanta VA Medical Center, Atlanta, Georgia (Dr Mavromatis), and Division of Cardiology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Saw).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati
What's this?
RELATED LETTERS
Pioglitazone vs Glimepiride in the PERISCOPE Trial
Claudio Fresco
JAMA. 2008;300(7):787.
EXTRACT
| FULL TEXT
Pioglitazone vs Glimepiride in the PERISCOPE Trial
Rahman Shah
JAMA. 2008;300(7):787-788.
EXTRACT
| FULL TEXT
Pioglitazone vs Glimepiride in the PERISCOPE Trial—Reply
Steven E. Nissen, Stephen J. Nicholls, and Kathy Wolski
JAMA. 2008;300(7):788.
EXTRACT
| FULL TEXT
RELATED ARTICLE
Does PERISCOPE Provide a New Perspective on Diabetic Treatment?
Philippe Gabriel Steg and Michel Marre
JAMA. 2008;299(13):1603-1604.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Efficacy and safety of pioglitazone in patients with ST elevation myocardial infarction treated with primary stent implantation
Kaneda et al.
Heart 2009;95:1079-1084.
ABSTRACT
| FULL TEXT
A Randomized Trial of Therapies for Type 2 Diabetes and Coronary Artery Disease
The BARI 2D Study Group
NEJM 2009;360:2503-2515.
ABSTRACT
| FULL TEXT
Effect of Ramipril and of Rosiglitazone on Carotid Intima-Media Thickness in People With Impaired Glucose Tolerance or Impaired Fasting Glucose STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).
Lonn et al.
J Am Coll Cardiol 2009;53:2028-2035.
ABSTRACT
| FULL TEXT
STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone) Is the Biggest Big Enough?
Kaski and Cockerill
J Am Coll Cardiol 2009;53:2036-2038.
FULL TEXT
A Prospective, Multicenter, Randomized Trial to Assess Efficacy of Pioglitazone on In-Stent Neointimal Suppression in Type 2 Diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study)
Takagi et al.
J Am Coll Cardiol Intv 2009;2:524-531.
ABSTRACT
| FULL TEXT
Pioglitazone to Reduce Restenosis After Bare-Metal Stent Placement?
Nissen
J Am Coll Cardiol Intv 2009;2:532-533.
FULL TEXT
Atherosclerosis in LDLR-Knockout Mice Is Inhibited, but Not Reversed, by the PPAR{gamma} Ligand Pioglitazone
Nakaya et al.
Am. J. Pathol. 2009;174:2007-2014.
ABSTRACT
| FULL TEXT
Achieving Glycemic Control: Cornerstone in the Treatment of Patients With Multiple Metabolic Risk Factors
Spellman
JAOA: Journal of the American Osteopathic Association 2009;109:S8-S13.
ABSTRACT
| FULL TEXT
Rosiglitazone Is Associated with Mortality in Chronic Hemodialysis Patients
Ramirez et al.
J. Am. Soc. Nephrol. 2009;20:1094-1101.
ABSTRACT
| FULL TEXT
Peroxisome Proliferator-Activated Receptor {gamma} Activation Restores Islet Function in Diabetic Mice through Reduction of Endoplasmic Reticulum Stress and Maintenance of Euchromatin Structure
Evans-Molina et al.
Mol. Cell. Biol. 2009;29:2053-2067.
ABSTRACT
| FULL TEXT
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2009;53:1326-1337.
FULL TEXT
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
DeFronzo
Diabetes 2009;58:773-795.
FULL TEXT
Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis.
Chhatriwalla et al.
J Am Coll Cardiol 2009;53:1110-1115.
ABSTRACT
| FULL TEXT
Review: Durable glycaemia -- the promised land
Campbell
British Journal of Diabetes & Vascular Disease 2009;9:53-63.
ABSTRACT
Defining the role of basal and prandial insulin for optimal glycemic control.
Horton
J Am Coll Cardiol 2009;53:S21-S27.
ABSTRACT
| FULL TEXT
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke et al.
CMAJ 2009;180:32-39.
ABSTRACT
| FULL TEXT
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients
Fruchart et al.
Diabetes and Vascular Disease Research 2008;5:319-335.
ABSTRACT
PERISCOPE and the effect of pioglitazone on the progression of coronary artery disease in patients with diabetes
Marx
Diabetes and Vascular Disease Research 2008;5:345-346.
The Peroxisome Proliferator-Activated Receptor-{gamma} Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-{alpha}-Dependent Manner In Vitro and In Vivo in Mice
Orasanu et al.
J Am Coll Cardiol 2008;52:869-881.
ABSTRACT
| FULL TEXT
Pioglitazone vs Glimepiride in the PERISCOPE Trial
Fresco
JAMA 2008;300:787-787.
FULL TEXT
Pioglitazone vs Glimepiride in the PERISCOPE Trial
Shah
JAMA 2008;300:787-788.
FULL TEXT
A Practical 'ABCDE' Approach to the Metabolic Syndrome
Blaha et al.
Mayo Clin Proc. 2008;83:932-943.
ABSTRACT
| FULL TEXT
Best Practices for Lowering the Risk of Cardiovascular Disease in Diabetes
Triplitt and Alvarez
Diabetes Spectr. 2008;21:177-189.
ABSTRACT
| FULL TEXT
All you need to read in the other general journals
BMJ 2008;336:798-799.
FULL TEXT
Does PERISCOPE Provide a New Perspective on Diabetic Treatment?
Steg and Marre
JAMA 2008;299:1603-1604.
FULL TEXT
Slowing Progression of Atherosclerosis in Diabetic Patients
JWatch General 2008;2008:1-1.
FULL TEXT
Pioglitazone vs. Glimepiride for Atherosclerosis in Diabetes
Journal Watch Cardiology 2008;2008:3-3.
FULL TEXT
|
